BiotechTube

SHR4640 + Allopurinol

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout

Conditions

Gout

Trial Timeline

Jun 15, 2021 โ†’ Aug 23, 2024

NCT ID
NCT04956432

About SHR4640 + Allopurinol

SHR4640 + Allopurinol is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT04956432. Target conditions include Gout.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04956432Phase 3Completed

Competing Products

20 competing products in Gout

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
77
Dotinurad + FebuxostatEisaiPhase 3
77
BaricitinibEli LillyPhase 2
52
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
33
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
52
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
33
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
33
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
77
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
33
SHR4640 ๏ผ›Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
52
SHR4640Jiangsu Hengrui MedicinePhase 1
33
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
77
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
33
Zurampicยฎ + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
23
Risk of selected safety eventsAstraZenecaPre-clinical
23
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
33
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
52
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
41
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
77

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85